B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-

B-cell Non-hodgkin Lymphoma Pipeline constitutes 75+ key companies continuously working towards developing 80+ B-cell Non-hodgkin Lymphoma treatment therapies, analyzes DelveInsight.

B-cell Non-hodgkin Lymphoma Overview:

B-cell non-Hodgkin lymphoma (NHL) is a cancer that originates from abnormal B lymphocytes, a type of white blood cell crucial to the immune system. It is the most common form of NHL, representing over 85% of cases. B-cell NHL can be classified into various subtypes based on the appearance of the cancer cells, the proteins on their surface, and their genetic characteristics. The most common subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. This cancer can develop in lymph nodes or other lymphoid tissues and may spread to extralymphatic organs, such as the gastrointestinal tract. Symptoms of B-cell NHL include painless lymph node swelling, unexplained fever, night sweats, fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. When these symptoms occur together, they are referred to as B symptoms, which are important for the disease's prognosis and staging.

Diagnosing B-cell non-Hodgkin lymphomas, particularly those with small- to intermediate-sized cells, is challenging due to their similarity in appearance to reactive lymphadenopathies and other lymphoma subtypes. Techniques like immunohistochemistry and flow cytometry are essential for accurate diagnosis but need to be interpreted alongside morphological and clinical information to avoid mistakes. Recognizing specific cytologic features is vital to guide the selection of these tests. Commonly misidentified B-cell non-Hodgkin lymphomas based on cytology alone include marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, and lymphoplasmacytic lymphoma. Because of these complexities, a lymph node biopsy is often required for a definitive diagnosis and classification of the lymphoma.

Request for a detailed insights report on B-cell Non-hodgkin Lymphoma pipeline insights @ https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"B-cell Non-hodgkin Lymphoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-cell Non-hodgkin Lymphoma Therapeutics Market.

Key Takeaways from the B-cell Non-hodgkin Lymphoma Pipeline Report

DelveInsight's B-cell Non-hodgkin Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for B-cell Non-hodgkin Lymphoma treatment.
In May 2023, Bristol Myers Squibb announced positive topline results from two studies: TRANSCEND FL, a global, multicenter Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1 study assessing Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met the primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
In May 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation CAR T-cell therapies for treating B-cell malignancies.
In May 2023, Genmab A/S revealed that the FDA approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, after two or more lines of systemic therapy.
In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech to continue their collaboration and option agreement under revised terms, leading to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023.
Key B-cell Non-hodgkin Lymphoma companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others are evaluating new drugs for B-cell Non-hodgkin Lymphoma to improve the treatment landscape.
Promising B-cell Non-hodgkin Lymphoma pipeline therapies in various stages of development include Valemetostat, MB-106, CB-010, LP-284, and others.

B-cell Non-hodgkin Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the B-cell Non-hodgkin Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Non-hodgkin Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-cell Non-hodgkin Lymphoma market.

Download our free sample page report on B-cell Non-hodgkin Lymphoma pipeline insights @ https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

B-cell Non-hodgkin Lymphoma Emerging Drugs

Valemetostat: Daiichi Sankyo
MB-106: Mustang Bio
CB-010: Caribou Biosciences
LP-284: Lantern Pharma

B-cell Non-hodgkin Lymphoma Companies

Over 75 key companies are working on developing therapies for B-cell non-Hodgkin lymphoma. Among them, Daiichi Sankyo has drug candidates for B-cell non-Hodgkin lymphoma in the advanced Phase II stage.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

B-cell Non-hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

B-cell Non-hodgkin Lymphoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging B-cell Non-hodgkin Lymphoma Therapies and Key Companies: B-cell Non-hodgkin Lymphoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

B-cell Non-hodgkin Lymphoma Pipeline Therapeutic Assessment
• B-cell Non-hodgkin Lymphoma Assessment by Product Type
• B-cell Non-hodgkin Lymphoma By Stage
• B-cell Non-hodgkin Lymphoma Assessment by Route of Administration
• B-cell Non-hodgkin Lymphoma Assessment by Molecule Type

Download B-cell Non-hodgkin Lymphoma Sample report to know in detail about the B-cell Non-hodgkin Lymphoma treatment market @ B-cell Non-hodgkin Lymphoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. B-cell Non-hodgkin Lymphoma Current Treatment Patterns
4. B-cell Non-hodgkin Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. B-cell Non-hodgkin Lymphoma Late-Stage Products (Phase-III)
7. B-cell Non-hodgkin Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-cell Non-hodgkin Lymphoma Discontinued Products
13. B-cell Non-hodgkin Lymphoma Product Profiles
14. B-cell Non-hodgkin Lymphoma Key Companies
15. B-cell Non-hodgkin Lymphoma Key Products
16. Dormant and Discontinued Products
17. B-cell Non-hodgkin Lymphoma Unmet Needs
18. B-cell Non-hodgkin Lymphoma Future Perspectives
19. B-cell Non-hodgkin Lymphoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the B-cell Non-hodgkin Lymphoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.